Sign In
Buy EDIT
$2.78
-0.0400 (-1.42%)
At Close: Jun 03, 2026
Why Editas Medicine's Shares Fell 28.9% This Week
03:52pm, Friday, 13'th May 2022 The Motley Fool
The company's progress for its lead therapy has been slow.
These 5-Stock Samplers Have Gotten Whacked. And That's OK
02:32pm, Friday, 13'th May 2022 The Motley Fool
It's all part of investing.
Editas' (EDIT) EDIT-301 Gets Orphan Drug Tag for Beta Thalassemia
02:30pm, Friday, 13'th May 2022 Zacks Investment Research
The FDA bestows an Orphan Drug designation to Editas' (EDIT) investigational gene therapy, EDIT-301, for treating beta thalassemia. Shares up in after-hours trading.
Editas' (EDIT) EDIT-301 Gets Orphan Drug Tag for Beta Thalassemia
12:02pm, Friday, 13'th May 2022
The FDA bestows an Orphan Drug designation to Editas' (EDIT) investigational gene therapy, EDIT-301, for treating beta thalassemia. Shares up in after-hours trading.
Why Editas Medicine's Shares Fell 28.9% This Week
11:52am, Friday, 13'th May 2022
The company's progress for its lead therapy has been slow.
Editas Medicine Receives FDA Orphan Drug Designation for EDIT-301 for the Treatment of Beta Thalassemia
08:30pm, Thursday, 12'th May 2022 GlobeNewswire Inc.
Company on track to dose first transfusion-dependent beta thalassemia patient with EDIT-301 by year-end Company on track to dose first transfusion-dependent beta thalassemia patient with EDIT-301 by y
Expert Ratings for Editas Medicine
04:02pm, Monday, 09'th May 2022 Benzinga
Editas Medicine (NASDAQ:EDIT) has observed the following analyst ratings within the last quarter:
Bullish
Somewhat Bullish
Indifferent
Somewhat Bearish
Bearish
Total Ratings
1
1
1
2
0
Last
Editas Medicine Presents Preclinical Data on EDIT-103 for Rhodopsin-associated Autosomal Dominant Retinitis Pigmentosa at the Association for Research in Vison and Ophthalmology Conference
05:30pm, Wednesday, 04'th May 2022 GlobeNewswire Inc.
Studies in non-human primates demonstrated nearly 100% gene editing knockout of endogenous RHO gene and more than 30% replacement protein levels
Editas' (EDIT) Q1 Loss Narrows, Revenues Beat Estimates
03:54pm, Wednesday, 04'th May 2022 Zacks Investment Research
Editas (EDIT) reports narrower-than-expected loss in the first quarter of 2022 while its revenues beat estimates. Focus on lead candidate, EDIT-101.
Editas' (EDIT) Q1 Loss Narrows, Revenues Beat Estimates
01:32pm, Wednesday, 04'th May 2022
Editas (EDIT) reports narrower-than-expected loss in the first quarter of 2022 while its revenues beat estimates. Focus on lead candidate, EDIT-101.
Editas Medicine (EDIT) Reports Q1 Loss, Tops Revenue Estimates
11:55am, Wednesday, 04'th May 2022 Zacks Investment Research
Editas (EDIT) delivered earnings and revenue surprises of 8.64% and 44.06%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Editas Medicine, Inc. (EDIT) CEO Jim Mullen on Q1 2022 Results - Earnings Call Transcript
11:23am, Wednesday, 04'th May 2022
Editas Medicine, Inc. (NASDAQ:EDIT ) Q1 2022 Results Earnings Conference Call May 4, 2022 8:00 AM ET Company Participants Ron Moldaver - Investor Relations Jim Mullen - Chief Executive Officer Mark Sh
Editas Medicine Announces First Quarter 2022 Results and Business Updates
10:45am, Wednesday, 04'th May 2022 GlobeNewswire Inc.
Appointed Gilmore O’Neill as CEO effective June 1, 2022; James C. Mullen to serve as Executive Chairman
Editas Medicine (EDIT) Reports Q1 Loss, Tops Revenue Estimates
09:02am, Wednesday, 04'th May 2022
Editas (EDIT) delivered earnings and revenue surprises of 8.64% and 44.06%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Editas Medicine to Present Pipeline and Platform Data Demonstrating Progress Towards Developing Transformative Gene Editing Medicines at the American Society of Gene and Cell Therapy Annual Meeting
08:31pm, Monday, 02'nd May 2022 GlobeNewswire Inc.
CAMBRIDGE, Mass., May 02, 2022 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, today announced that four abstracts have been accepted for presentation, in
